
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is a diversified healthcare company, operating across four segments including Established Pharmaceuticals, Nutritionals, Diagnostics, and Medical Devices. The company has a strong product portfolio and pipeline in high-growth areas such as Diabetes, Structural Heart and Diagnostics, and is well positioned for accelerating growth in FY27. With a focus on sustainability and a strong cash generation, Abbott is highly attractive as a GARP large-cap medtech name, trading at ~14.5x'27E consensus EPS, lower than the peer group.
Bears say
Abbott Laboratories is heavily reliant on sales outside the United States, which exposes it to risks related to economic, competitive, and geopolitical events. Additionally, product safety concerns and product liability claims pose a significant risk to profitability, and the declining sales in the Nutritional Products segment indicate potential struggles in transitioning to a volume-driven growth strategy. Overall, these factors contribute to a negative outlook for Abbott's stock, with limited growth potential and potential for significant liabilities in the future.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares